Report
Luis Arredondo
EUR 100.00 For Business Accounts Only

GRIFOLS: VERTEX ABANDONS VX-864 DEVELOPMENT (ANÁLISIS BANCO SABADELL)

Last night, the US laboratory Vertex announced it will abandon its phase II VX-864 study for alpha 1-antitrypsin deficit
Underlying
Provider
Sabadell
Sabadell

Analysts
Luis Arredondo

Other Reports on these Companies
Other Reports from Sabadell

ResearchPool Subscriptions

Get the most out of your insights

Get in touch